Literature DB >> 11574199

Comparative safety of the different macrolides.

E Rubinstein1.   

Abstract

The macrolides are generally well tolerated when used for the treatment of acute infections. Even when given long term for prophylaxis, there are few discontinuations due to side-effects. There are isolated reports of QT(c) prolongation in patients treated with erythromycin and other 14-membered-ring macrolides. Since the 14-membered-ring macrolides are metabolized by P450 isoenzymes, there is the potential for interaction with other therapeutic agents also metabolized in this way. Pharmacokinetic studies have demonstrated interactions between either erythromycin or clarithromycin and cyclosporin, cisapride, pimozide, disopyramide, astemizole, carbamazepine, midazolam, digoxin, hydroxymethylglutaryl-coenzyme A reductase inhibitors (i.e. 'statins') and warfarin. In patients receiving such concurrent therapy, azithromycin may be superior to erythromycin and clarithromycin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574199     DOI: 10.1016/s0924-8579(01)00397-1

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  17 in total

1.  Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency.

Authors:  Tongtong Yu; Tiesheng Niu
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

2.  Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.

Authors:  Jeffrey K Aronson
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

3.  Neurological and Psychiatric Adverse Effects of Antimicrobials.

Authors:  Madison K Bangert; Rodrigo Hasbun
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

4.  Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis.

Authors:  Jean M Larson; Anna Tavakkoli; Walter E Drane; Phillip P Toskes; Baharak Moshiree
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

Review 5.  Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Authors:  Quan Zhou; Xiao-Feng Yan; Zhong-Miao Zhang; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

6.  Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.

Authors:  Espen Molden; Eva Skovlund; Pia Braathen
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys.

Authors:  Kenji Yogo; Mitsu Onoma; Ken-Ichi Ozaki; Masao Koto; Zen Itoh; Satoshi Omura; Hisanori Takanashi
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

8.  Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors.

Authors:  Anna Kezerashvili; Himad Khattak; Aron Barsky; Reza Nazari; John D Fisher
Journal:  J Interv Card Electrophysiol       Date:  2007-06-02       Impact factor: 1.900

9.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

10.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.